Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection

US6319666A · kind A · utility

Assignee

• Erasmus Universiteit Rotterdam · NL

Inventors

• Carel A. van Baalen · Zeewolde, NL
• Albertus D. M. E. Osterhaus · Bunnik, NL

Key dates

• Filing date: Jun 17, 1999
• Grant date: Nov 20, 2001
• Expiry date: Jun 17, 2019

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16322
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presence of cytotoxic T-cells to the Rev and/or Tat protein in samples from a subject infected with immunodeficiency virus, particularly HIV in humans, is an indication of a stable disease condition and a favorable prognosis of lack of progression to disease. Immunogenic compositions containing at least one cytotoxic T-cell epitope of the Rev and/or Tat protein of an immunodeficiency virus, particularly HIV, or a vector encoding the T-cell epitope, may be used to prevent infection by disease caused by the immunodeficiency virus, by stimulating, in the host, a specific cytotoxic T-cell response specific for the respective Rev and/or Tat proteins.